Ready-to-use hiPSC-derived cells streamline lab workflows

AMSBIO has introduced a new range of fully differentiated human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes, hepatocytes, and neurons, designed to streamline laboratory workflows. These ready-to-use cells eliminate the need for in-house differentiation, significantly reducing preparation time and enhancing research efficiency.

With functional validation performed prior to delivery, researchers can confidently incorporate these cells into their assays without additional optimisation. This is particularly beneficial for Contract Research Organizations (CROs) and life science laboratories, enabling them to save both time and costs associated with validation processes.

AMSBIO’s hiPSC-derived cells offer exceptional batch-to-batch consistency, ensuring reliable experimental outcomes. By providing a physiologically relevant alternative to primary cells and animal models, these cells support a wide range of applications, including drug discovery, disease modelling, and toxicity screening.

More information online